EDINBURGH, Scotland, Dec. 31,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage
biotechnology company developing platform allogeneic gamma-delta
T-cell therapies for cancer and other indications, today announced
it has advanced negotiations with both of its previously
aforementioned acquisition candidates.
This past spring TCBP announced the execution of non-binding
letters of intent as part of its M&A strategy aimed at
expanding its therapeutic platform. The Company continues to pursue
its expansion strategy via acquisition, specifically in new
indications and new cell therapy modalities.
TCBP will be focusing its acquisition efforts on two main areas;
Natural Kill cell technologies and CAR-related technologies. The
Company intends to move forward with near-term acquisition
opportunities in the NK space, reviewing several new opportunities
in the allogeneic NK space as well as the CAR-NK space. This would
expand the Company's efforts into autoimmune disease as well as
additional opportunities in solid tumors and combination therapies
using both TCB008 and an allogeneic NK cell in combination.
Additionally, the Company is pursuing new opportunities in the
novel CAR space. TCB008 is an ideal candidate to be modified with
new CAR technologies further to enhance its efficacy in solid
tumors and other cancers. Expanding TCB008 into a CAR-modified cell
increases the use case and economies of scale for the therapeutic
and furthers the use of our manufacturing site, where we have room
for expansion.
"TC BioPharm is encouraged by the progress that we have made
during these discussions with our current acquisition targets,"
said Bryan Kobel, Chief Executive
Officer. "We are pursuing companies that have
developed proprietary approaches to their specific areas of
treatment and would significantly enhance TCBP's treatment platform
while meshing with our current offerings. Management is
currently negotiating deal terms in good faith, and I believe the
process is progressing to mutually beneficial outcomes. We
hope to have additional updates soon as we remain committed to
establishing ourselves as a leader in novel oncology
treatments."
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on discovering, developing, and commercializing gamma-delta
T-cell therapies for cancer treatment with human efficacy data in
acute myeloid leukemia. Gamma-delta T cells are naturally occurring
immune cells that embody properties of both the innate and adaptive
immune systems and can intrinsically differentiate between healthy
and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T-cell product line - Phase 2b/3 pivotal trial in the treatment of acute
myeloid leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the Company's intent or ability to affect any
budget savings or execute on any M&A or capital raising
strategy. These statements are based on management's current
assumptions and are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this Current Report
on Form 8-K. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-provides-update-on-acquisition-strategy-and-current-targets-302340660.html
SOURCE TC BioPharm
